ICON Public (NASDAQ:ICLR) Sets New 1-Year Low – What’s Next?

ICON Public Limited (NASDAQ:ICLR) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $179.50 and last traded at $184.41, with a volume of 158879 shares traded. The stock had previously closed at $190.02.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. Robert W. Baird lowered their price objective on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating for the company in a research report on Tuesday. Barclays lowered their target price on ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a report on Friday, February 21st. Citigroup lowered their price target on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. Finally, Leerink Partners reissued an “outperform” rating and issued a $255.00 price target (down from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, ICON Public presently has an average rating of “Moderate Buy” and a consensus price target of $279.17.

ICON Public Stock Up 1.6 %

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The company has a market capitalization of $15.06 billion, a P/E ratio of 19.57, a PEG ratio of 1.86 and a beta of 1.19. The stock has a 50 day moving average price of $200.78 and a 200 day moving average price of $238.28.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.01. The company had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. Equities research analysts forecast that ICON Public Limited will post 13.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Institutional investors and hedge funds have recently made changes to their positions in the business. Sierra Ocean LLC bought a new position in shares of ICON Public in the fourth quarter worth approximately $29,000. Park Place Capital Corp raised its position in shares of ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after buying an additional 166 shares in the last quarter. Private Trust Co. NA lifted its holdings in shares of ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after acquiring an additional 82 shares during the last quarter. GAMMA Investing LLC grew its position in ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its position in ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after acquiring an additional 151 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.